WASHINGTON (AP) — When a powerful pair of cholesterol-lowering drugs first hit the market last summer, initial excitement in the medical community quickly turned to panic. The new drugs promised to ...

LONDON, July 24 (Reuters) - A new type of cholesterol drug from Sanofi and Regeneron Pharmaceuticals won a green light from European regulators on Friday, two months behind a rival product from Amgen.

Amgen, Sanofi and Regeneron would need to lower the list price of their cholesterol-lowering drugs by more than two-thirds to ensure the treatments are cost-effective in the U.S., according to a new ...

(Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its ...

(Reuters) - Amgen Inc sells its cholesterol-lowering drug Repatha at a discount of about 30 percent to its U.S. list price of $14,000 a year, but the largest pharmacy benefit managers say they want ...

The Food and Drug Administration on Tuesday approved a once-monthly dose form of the cholesterol drug Praluent. The drug, co-developed by Regeneron Pharmaceuticals and Sanofi, first earned FDA ...